Activation of Murine CD4 and CD8 T Lymphocytes Leads to Dramatic ...

The Journal of Immunology

Activation of Murine CD4ⴙ and CD8ⴙ T Lymphocytes Leads to Dramatic Remodeling of N-Linked Glycans1 Elena M. Comelli,2* Mark Sutton-Smith,‡ Qi Yan,* Margarida Amado,* Maria Panico,‡ Tim Gilmartin,† Thomas Whisenant,† Caroline M. Lanigan,† Steven R. Head,† David Goldberg,§ Howard R. Morris,3‡ Anne Dell,‡ and James C. Paulson4* Differentiation and activation of lymphocytes are documented to result in changes in glycosylation associated with biologically important consequences. In this report, we have systematically examined global changes in N-linked glycosylation following activation of murine CD4 T cells, CD8 T cells, and B cells by MALDI-TOF mass spectrometry profiling, and investigated the molecular basis for those changes by assessing alterations in the expression of glycan transferase genes. Surprisingly, the major change observed in activated CD4 and CD8 T cells was a dramatic reduction of sialylated biantennary N-glycans carrying the terminal NeuGc␣2-6Gal sequence, and a corresponding increase in glycans carrying the Gal␣1-3Gal sequence. This change was accounted for by a decrease in the expression of the sialyltransferase ST6Gal I, and an increase in the expression of the galactosyltransferase, ␣1-3GalT. Conversely, in B cells no change in terminal sialylation of N-linked glycans was evident, and the expression of the same two glycosyltransferases was increased and decreased, respectively. The results have implications for differential recognition of activated and unactivated T cells by dendritic cells and B cells expressing glycan-binding proteins that recognize terminal sequences of N-linked glycans. The Journal of Immunology, 2006, 177: 2431–2440.

D

ifferentiation and activation of lymphocytes are accompanied by programmed remodeling of cell surface glycans of glycoproteins with biologically important consequences. Notably, the conversion of the peanut agglutinin (PNA)5 high (PNAhigh) phenotype of immature CD4/CD8 medullary thymocytes to the PNAlow phenotype of the mature singlepositive CD8 and CD4 thymocytes results from conversion of the PNA ligand, the O-linked glycan Gal␤1-3GalNAc␣Thr/Ser, to its sialylated form, NeuAc␣2–3Gal␤1-3GalNAc␣Thr/Ser, that is no longer recognized by PNA due to increased expression of a sialyltransferase, ST3Gal I (1– 4). In CD8 T cells, this glycosylation change reduces the affinity of CD8 for MHC class I, suggesting that sialylation of CD8 O-glycans modulates CD8 function during selection and maturation of CD8 T cells (5–7). Naive CD8 cells of *Departments of Molecular Biology and Molecular and Experimental Medicine and † DNA Microarray Core Facility, The Scripps Research Institute, La Jolla, CA 92037; ‡ Division of Molecular Biosciences, Imperial College, London, United Kingdom; and § Scripps-Palo Alto Research Center Institute for Advanced Biomedical Sciences, Palo Alto, CA 94304 Received for publication February 17, 2006. Accepted for publication April 26, 2006. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 This work was supported by National Institutes of Health Grants AI50143 (to J.C.P.) and GM074128 (to D.G.) and by research grants from the Biotechnology and Biological Sciences Research Council and the Wellcome Trust (to H.R.M. and A.D.). Microarray analysis was performed by the Microarray Core of the Consortium for Functional Glycomics (GM62116). A.D. is a Biotechnology and Biological Sciences Research Council Professorial Fellow. 2

Current address: Nestle´ Research Centre, Lausanne, Switzerland.

3

Current address: M-SCAN Mass Spectrometry Research and Training Centre, Silwood Park, Ascot SL5 7PZ, U.K. 4 Address correspondence and reprint requests to Dr. James C. Paulson, Department of Molecular Biology and Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, MEM-L71, La Jolla, CA 92037. E-mail address: [email protected] 5 Abbreviations used in this paper: PNA, peanut agglutinin; MS, mass spectrometry; SNA, Sambucus nigra agglutinin; GS, Griffonia simplicifolia; RMA, robust multiarray analysis.

Copyright © 2006 by The American Association of Immunologists, Inc.

ST3Gal Inull mice that are constitutively PNAhigh undergo rapid apoptosis in the periphery, reducing the CD8 population to 10% of wild type (2). Yet, conversion from PNAlow to PNAhigh is a natural consequence of activation of wild-type CD8 cells resulting from down-regulation of ST3Gal I (2, 8, 9). In contrast, ST3Gal I is differentially regulated in activated and polarized Th1 and Th2 CD4 cells leading to the PNAhigh and PNAlow phenotype, respectively (10). The additional increased expression of fucosyl- and sialyltransferases in Th1 cells promotes synthesis of the selectin ligand sialyl-Lewis X (NeuAc␣2-3Gal␤1-4[Fuca1-3]GlcNAc), while Th2 helper cells lack sialyl-Lewis X sequences because a key fucosyltransferase, Fuc-T VII, is not expressed. Such differential glycosylation accounts for the selectin-mediated recruitment of CD4 Th1 cells to sites of inflammation (11–17). Insights into the importance of N-linked glycan structures in lymphocyte biology have also been obtained by ablation or overexpression of key glycosyltransferases. For example, ablation of the GlcNAc transferase Mgat5 leads to increased TCR signaling and autoimmune disease, and promotes Th2 over Th1 responses, a result of the loss of N-linked glycans with a GlcNAc␤1-6Man branch that interacts with galectins and reduces TCR signaling by restricting TCR clustering (18). A sialyltransferase that elaborates the terminal sequence NeuAc␣2-6Gal␤1-4GlcNAc on N-linked and O-linked glycans has been shown to block the binding of galectin-1 that induces T cell death by clustering of CD45 and reduction of its phosphatase activity (19). The same sequence has been documented to be the glycan ligand for CD22 (Siglec-2), a regulator of B cell signaling, that has been proposed to mediate adhesion of B cells to T cells (20 –25). The expression of the enzyme responsible for the synthesis of the sequence, ST6Gal I, was noted to be down-regulated in a microarray analysis of Ag-activated CD8 cells, but the consequences on the structures of CD8 cell glycans were not investigated (26). Despite the importance of glycosylation in lymphocyte function, changes in glycosylation are largely studied through indirect means such as probing for the presence or absence of specific 0022-1767/06/$02.00

2432 glycan sequences with plant or animal lectins or carbohydratespecific Abs. Although this approach has provided biologically important information, it is limited to examining aspects of structure relevant to the specificity of the probes used, and does not address the extent to which changes occur. Indeed, there have been few investigations of glycosylation changes in lymphocytes in which direct analysis of glycan structure has been conducted. An exception is a rigorous analysis conducted nearly 20 years ago investigating the O-linked glycans of human leukosialin before and after activation of human T cells (27). This study revealed that the predominant disialylated “core 1” glycans of naive T cells (NeuAc␣2-3Gal␤1-3(NeuAc␣2-6)GalNAc␣Thr/Ser) were replaced by larger branched “core 2” structures (NeuAc␣2-3Gal␤13[NeuAc␣2-3Gal␤1-4GlcNAc␤1-6] GalNAc␣Thr/Ser) in activated cells (27), now known to be the nonfucosylated precursor of the O-linked sialyl-Lewis X ligand of P-selectin (28). The change was concluded to result from altered expression of two glycosyltransferases that form the NeuAc␣2-6GalNAc linkage and GlcNAc␤1-6GalNAc linkages, enzymes that compete to form the alternative branch points in these structures, respectively. In principle, such analysis can now be conducted by high throughput methods for assessment of glycan structure and expression of the glycosyltransferase genes responsible for their synthesis (29). To this end, we have investigated changes in glycosylation of N-linked glycans of resting and activated murine T and B lymphocytes using MALDI-TOF mass spectrometry (MS) profiling for assessment of glycan structure, and a custom gene microarray based on Affymetrix technology, developed and annotated by the Consortium for Functional Glycomics (具www.functionalgly comics.org典) for evaluating changes in expression of glycosyltransferase genes. A dramatic change was observed in the terminal glycosylation pattern of N-linked glycans of CD4 and CD8 T cells. In freshly isolated cells, the predominant complex type N-glycans contained terminal sialic acid, in the NeuGc␣2-6Gal sequence that forms the ligand of murine CD22 and is implicated in regulation of galectin-mediated cell death. In contrast, the activated cells exhibited a dramatic decrease in sialylated glycans, and a corresponding increase in glycans with the Gal␣1-3Gal terminal sequence. Gene microarray analysis revealed that the changes in N-glycan structures in activated T cells corresponded to changes in the expression of a sialyltransferase and galactosyltransferase responsible for the synthesis of these terminal structures. The approach of using MALDI-TOF MS for profiling glycan structure coupled with gene microarray analysis to survey glycosyltransferase expression may prove to be a powerful combination for investigating glycosylation changes in differentiating or activated cells.

Materials and Methods Preparation and culture of splenocytes C57BL/6 male mice (6 –10 wk old) were obtained from The Scripps Research Institute Custom Breeding core and used to prepare splenocytes, as previously described (9). In this report, fresh cells refer to cells not subjected to cell culture, and resting and activated cells are those subjected to cell culture in the absence or presence of activating agents, respectively. For T cell activation experiments, splenocytes were plated (108 cells/plate) with immobilized anti-CD3 (BD Pharmingen) and cultured for 72 h in RPMI 1640 medium supplemented with either 4 ng/ml IL-2 and 5 ng/ml IL-12, or 4 ng/ml IL-2 and 10 ng/ml IL-4, or 4 ng/ml IL-2 (R&D Systems). For B cell activation, splenocytes were cultured for 72 h in RPMI 1640 medium supplemented with 10 ␮g/ml anti-IgM (Jackson ImmunoResearch Laboratories) and 10 ng/ml IL-4.

Lymphocyte purification CD4 and CD8 T cells and B cells were purified from either fresh, resting, or activated splenocytes using the MidiMACS system (Miltenyi Biotec) by positive selection, according to the manufacturer’s protocols.

GLYCOSYLATION CHANGES IN ACTIVATED LYMPHOCYTES Briefly, cells were resuspended in PBS containing 5 mg/ml BSA and 2 mM EDTA and incubated with anti-CD4, anti-CD8, or anti-CD19 microbeads for 15 min at 4°C for purification of CD4, CD8 T cells, or B cells, respectively. After washing, cells were resuspended in the same buffer and applied to the column. Purity of cell preparations was always ⱖ90%, as judged by flow cytometry. Purified cells were either washed with PBS twice and immediately frozen and stored at ⫺80°C until use or immediately used for flow cytometry analysis.

Flow cytometry Purified CD4, CD8 T cells and B cells were incubated in aliquots of 5 ⫻ 105 cells in 100 ␮l of PBS containing 10 mg/ml BSA with or without GS-I-B4-FITC lectin from Griffonia simplicifolia (GS; EY Laboratories) at a concentration of 20 ␮g/ml or Sambucus nigra agglutinin (SNA) lectin (Vector Laboratories) at a concentration of 40 ␮g/ml, for 30 min on ice. Flow cytometry data were acquired on viability-gated cells using a FACSCalibur flow cytometer and analyzed with the CellQuest software system (BD Biosciences).

Analysis of glycan transferase gene expression Analysis of gene expression was conducted using a custom gene microarray (GLYCOv1 chip) produced by Affymetrix for the Consortium for Functional Glycomics (具www.functionalglycomics.org典), and containing probe sets for 122 glycosyl- and sulfotransferases (29). Three independent experiments were performed for each activation condition of each lymphocyte type (CD4, CD8, and B lymphocytes), resulting in triplicate RNA samples per condition. RNA was extracted using the Qiagen RNeasy mini kit according to the manufacturer’s protocol. After treatment with DNase I amplification grade (Invitrogen Life Technologies), total RNA was purified with RNeasy columns using the cleanup protocol (Qiagen) and was quality checked with an Agilent Bioanalyzer (Agilent Technologies). For glycosyltransferase expression analysis, 5 ␮g of total RNA was amplified and biotin-labeled using the Bioarray High Yield RNA Transcript Labeling kit (Enzo Life Sciences) and then hybridized to the GLYCOv1 chip. One chip per biological replicate was run. Hybridization and scanning of the chip were performed according to the Affymetrix recommended protocols. The MAS 5.0 algorithm (Affymetrix) was used to determine present (P) and absent (A) absolute calls for each sample. All marginal (M) calls were interpreted as absent. Genes were finally considered present if they had been assigned a present call in at least two of the three biological replicate samples (Group Call). Expression signals were then generated using the Robust MultiarrayAnalysisalgorithm(Ref.30and具http://stat-www.berkeley.edu/⬃bolstad/ RMAExpress/RMAExpress.html典). Unsupervised hierarchical clustering by sample was performed with BRB ArrayTools using the default settings for correlation and linkage (具http://linus.nci.nih.gov/BRB-ArrayTools.html典). Statistical comparisons were made for each gene to determine whether the signals in the fresh and activated samples were statistically significant. Accordingly, the robust multiarray analysis (RMA) signals of the triplicate fresh samples of each lymphocyte type were compared with the signals of the triplicate samples of each activation condition corresponding to that lymphocyte type. The CD4 and CD8 T cell experiments, which involved three different activation conditions, warranted the use of the Dunnett’s test, a modified t test, which controls for the “experiment wise” or “per experiment” error rate (31, 32). It does not produce a p value, rather the computed q⬘ value is compared against a table of Dunnett’s critical values determined for the appropriate ␣ value as follows:

q⬘ ⫽ tdunnett ⫽

x៮ Ac ⫺ x៮ i

冑

2MSE n

where: MSE ⫽

冘冘冉冘 s2i

k

冊

共 xi ⫺ x៮ 兲2 n⫺1 k

⫽

(1)

k is the number of groups, and n is the sample size. A two-tailed Dunnett’s test was applied. The critical values for ␣ ⫽ 0.05, k ⫽ 4 groups, degrees of freedom (error) ⫽ ␯e ⫽ (n ⫺ k) ⫽ (12 ⫺ 4) ⫽ 8, were:

q⬘ ⫽ tdunnett(2) ⫽ q⬘冉␣,ve,k冊 ⫽ q⬘冉0.05,8,4冊 ⫽ 2.88 2

2

(2)

For the B cell experiments, the two groups were fresh and activated, and a Student t test, assuming the variances were equal, was applied (the result of an Fmax test for variance on all probe sets was that the variance was


2433

equal for all but three cases, and in all three cases the variance was very small, with the control sample variance effectively 0):

tcritical(2) ⫽ t冉␣,v冊 ⫽ t冉0.05,4冊 ⫽ 2.776 2

2

(3)

Characterization of B and T lymphocytes N-glycans Approximately 25 million fresh and 15 million activated B and T lymphocytes, respectively, were used for each analysis. Cell preparations were homogenized, detergent extracted, reduced/carboxy methylated, dialyzed, and digested with trypsin as previously described (33). N-glycans were released from each proteolyzed extract by peptide:N-glycanase (PNGase F; Roche) treatment and were subsequently permethylated using the sodium hydroxide procedure, as described elsewhere (33). MALDI-TOF MS, electrospray MS/MS, and methylation analyses were then performed following previously published strategies (34).

ditions for T cells were chosen to determine whether early glycosylation changes were influenced by cytokines that promote CD4⫹ T cell polarization to Th1 (IL-2/IL-12) and Th2 (IL-2/IL-4) subsets. Lymphocytes were purified by positive selection using either anti-CD4-, anti-CD8-, or anti-CD19-coated magnetic microbeads for CD4 T cells, CD8 T cells, or B cells, respectively, yielding cell populations 90 –98% pure (Fig. 1). The remaining cells were discarded. Activated cells are compared with fresh lymphocytes because lymphocytes cultured in the absence of cytokines were subject to extensive cell death. Three independent experiments were done for each activation condition for mRNA extraction and microarray analysis, and at least two experiments for each activation condition were subjected for evaluation of N-glycan structure by MALDI-TOF MS analysis.

Results Strategy for analysis of changes in N-linked glycosylation

Analysis of N-glycans from fresh and activated lymphocytes

The overall strategy for analysis of changes in N-linked glycosylation was to activate freshly isolated mixed splenocytes in vitro for 72 h, purify the cell type of interest, and either subject the purified cells to glycan analysis, or extract mRNA for analysis on the glycogene microarray. Each preparation of lymphocytes involved pooling splenocytes from 10 to 30 mice, and subjecting them to activation conditions selected for T cell activation (anti-CD3 with IL-2/IL-12 or IL-2/IL-4) or B cell activation (anti-IgM with IL-2/ IL-4) as described in Materials and Methods. The activation con-

Portions of representative MALDI-TOF MS profiles showing the mass region with complex N-glycans are shown in Fig. 2 for fresh and activated T and B lymphocytes. Striking differences are observed upon comparison of fresh and activated CD8 and CD4 T cells as illustrated by the major peaks annotated in symbol format. The predominant peaks in the fresh cells are disialylated biantennary and monosialylated triantennary glycans. In contrast, the predominant peaks in the cells activated with IL-2/IL-12 are di- and tribranched structures disubstituted with dihexose termini. Similar

FIGURE 1. Purification of B cells and T cells from mixed splenocytes before and after activation. CD8 T cells, CD4 T cells, and B cells were purified from mixed splenocytes before or after activation using the MACS system with anti-CD8-, anti-CD4-, or anti-CD19-coated magnetic beads, respectively. Phenotypic analysis of purified fresh and activated cell populations was performed by flow cytometry and showed ⱖ90% purity of all cell preparations, as indicated. Purified cells were used either for RNA preparation for microarray analysis, or were processed to extract glycans for MALDI profiling and methylation analysis.

2434

GLYCOSYLATION CHANGES IN ACTIVATED LYMPHOCYTES profiles were observed for CD8 and CD4 T cells activated with IL-2/IL-4 (data not shown). As an example of the dramatic change between fresh and activated cells, note that the predominant peak representing the disialylated biantennary glycan at mass 3027 in fresh CD8 and CD4 cells is largely absent in the profiles of the corresponding activated cells. In contrast, the predominant dihexose-terminated biantennary glycan at mass 2653 in activated CD8 and CD4 cells is a minor peak in the profiles from fresh cells. More detailed annotations of the MS spectra, using the cartoonist algorithm (35), are provided in Fig. S1 (supplemental data).6 Further characterization of the major species by MS/MS analysis confirmed that the termini of the complex glycans were NeuGc-Hexose-HexNAc in the fresh cells and Hexose-HexoseHexNAc in the activated cells (data not shown). Methylation analysis revealed that there was a significant change in the substitution of galactose at the 6 and 3 positions for N-glycans of fresh and activated (IL-2/IL-12) CD8 T cells (Table I). Although the methylation analysis comprises results from all glycans including high mannose glycans, galactose occurs only as a penultimate or terminal residue, so the substitution pattern of the galactose residues provides direct information about the terminal substitutions on complex N-linked glycans. Substitution of galactose at the 6 position went from 42 to 9% of the total galactose in fresh and activated cells, respectively, while substitution at the 3 position went from 11 to 53%. Taken together with the MALDI-TOF data showing loss of sialic acids and an increase in terminal hexose, the data are consistent with the predominant terminal sequences on fresh and activated CD8 T cells as sequences previously reported on N-linked glycans of murine lymphocytes, NeuGc␣2-6Gal␤1-4GlcNAc (36, 37), and Gal␣1-3Gal␤1-4GlcNAc (38), respectively. In marked contrast to the dramatic changes in the major complex type N-glycans of fresh and activated T cells, there was little difference in the major N-linked glycans of fresh and activated B cells. In both fresh and activated B cells, the predominant structures were biantennary capped with one or two NeuGc residues. Altered expression of terminal Gal␣1-3Gal and NeuGc␣2-6Gal linkages in activated T cells

FIGURE 2. MALDI-MS profiles of N-glycans of fresh and activated T and B cells. Shown are comparisons of MALDI-MS profiles of Nlinked glycans from fresh (A, C, and E) and activated (B, D, and F) T and B cells. CD8 T cells (A and B) and, CD4 T cells (C and D), were activated with anti-CD3 and IL-2/IL-12, B cells (E and F) were activated with anti-IgM and IL-4. Major peaks representing complex type N-glycans of either the fresh or activated cells are annotated with structures in symbol form. Dramatic changes are evident in the profiles of both the activated T cell populations, while little change is evident following activation of B cells. More detailed annotations are given in supplemental data (Fig. S1).

To confirm that the Gal␣1-3Gal sequence did indeed increase following activation of CD8 and CD4 T cells, FACS analysis was performed using the GS-I-B4 lectin from G. simplicifolia, which exhibits high specificity for this sequence. As shown in Fig. 3, there was a 10- to 30-fold increase in binding of the GS-I-B4 lectin in activated T cells relative to resting T cells. This observation is consistent with the dramatic increase in the Gal␣1-3Gal sequence detected in analysis of the N-linked glycans (Fig. 2 and Table I). Conversely, there was an activation-dependent decrease in the Sia␣2-6Gal sequence in CD8 cells, as detected by the SNA lectin specific for this sequence. Although a significant change in SNA binding was not detected in CD4 cells, it is possible that the Sia␣26Gal sequence is also present on glycoproteins with O-linked glycans, and/or glycolipids, which are turning over slower than glycoproteins that comprise the majority of N-linked glycans profiled in Fig. 2. No change in binding of either the GS-I-B4 or SNA lectins to activated B cells relative to resting B cells was observed. Taken together, these phenotypic results are consistent with the increase in the Gal␣1-3Gal linkage and a decrease in the NeuGc␣2-6Gal sequences detected on activated T cells by direct analysis of N-linked glycans.

6

The online version of this article contains supplemental material.


2435

Table I. Methylation analysis of N-linked glycans of fresh and activated (IL-2/IL-12) CD8 T cells Relative Abundance Elution Time (Min)

18.73 19.92 20.43 18.47 19.62 20.02 20.81 21.19 21.36 16.95 22.28 23.18 24.02 24.48

Characteristic Fragment Ions

102, 101, 118, 102, 129, 118, 129, 129, 118, 102, 117, 117, 117, 117,

118, 118, 129, 118, 130, 129, 130, 130, 129, 118, 143, 159, 159, 159,

129, 129, 145, 129, 161, 145, 190, 189, 189, 131, 145, 233 346 261

145, 234 189, 145, 190, 189, 233 190 234 175 159,

161, 162, 205 233 161, 162, 205 234 233

203, 205

Microarray analysis of the expression of cytokine and glycan transferase genes For gene expression analysis, mRNAs were extracted from purified cell populations of fresh and activated lymphocytes and subjected to analysis on a custom Affymetrix-based DNA microarray containing murine and human glycosyltransferase, sulfotransferase, and cytokine genes, made available by the Consortium for Functional Glycomics. Three independent RNA preparations were made for each experimental condition comprising fresh and activated CD4 and CD8 T cells (anti-CD3 with IL-2, IL2/IL-12, or IL-2/IL-4) and B cells (anti-IgM with IL-2/IL-4) for a total of 30 separate RNA preparations. Labeled samples were prepared for each RNA and then hybridized to microarrays yielding three sets of data for fresh cells and each activation condition. Present and absent calls were assigned by the MAS 5.0 algorithm (Affymetrix), and a gene was deemed present if at least two of the three triplicate samples gave a present call (present call). Expression signals were generated using the RMA algorithm expressed in log 2 (30), and differences between expression in the fresh and activated cells were assessed for statistical significance and converted to “fold differences” for presentation. The GLYCOv1 chip also contained cytokine genes which allowed further confirmation of the programmed activation resulting from cytokines present during activation. The changes observed were consistent with the early (72 h) programmed changes in gene expression following in vitro activation of CD4 cells with IL-12 or IL-4 (39, 40). In particular, increased expression of the IL-4 and IL-13 genes was observed only in CD4 cells cultured with IL-4, consistent with a CD4 Th2 response. In contrast, expression of these genes was not detected in CD4 cells cultured with IL-12, but expression of the IFN-␥ gene is highest in these cells, consistent with the early stages of conversion to the Th1 subtype. Samples were compared for expression of 122 glycosyltransferase and sulfotransferase genes by unsupervised hierarchical cluster analysis as shown in Fig. 4. Expressions of genes in fresh B and activated B cells and fresh CD4 and CD8 T cells are more closely related to each other than activated CD4 and CD8 T cells, which cluster separately. Of the 122 glycan transferase genes evaluated, 52 genes exhibited one or more statistically significant differences between activated cells and the corresponding fresh cells (see Materials and Methods for statistical analysis and Table S1 available as supplemental data for a complete listing of results for all genes). Of these, 23 showed differences of ⬍1.5-fold, and 29 showed differences ⬎1.5-fold. Of the 23 with differences ⬍1.5-

Assignment

Fresh

IL-12

Terminal galactose 3-Galactose 6-Galactose Terminal mannose 2-Mannose 6-Mannose 2,4-Mannose 2,6-Mannose 3,6-Mannose Terminal fucose Terminal GlcNAc 4-GlcNAc 3,4-GlcNAc 4,6-GlcNAc

0.09 0.02 0.08 0.77 1.62 0.04 0.02 0.01 0.27 0.07 0.03 1.00 ⬍0.01 0.05

0.12 0.17 0.03 0.55 0.42 0.02 0.03 0.04 0.42 0.06 0.02 1.00 0.01 0.09

fold, 11 could be considered not meaningful (e.g., statistically significant differences between samples with all absent calls). However, for the 29 with differences ⬎1.5-fold, only one would be considered not meaningful. Of these, only 13 of the genes code for enzymes that are potentially relevant to the biosynthesis of Nlinked glycans, and the remainder are primarily relevant to the synthesis of other glycan classes including 5 for O-linked glycans, 4 for proteoglycans, 2 for glycolipids, 2 for glycophosphatidylinositol anchors, and 2 with undefined activity. Of the two genes coding for enzymes involved in terminal glycosylation of O-linked glycans (Table II), one is ST3Gal I, which

FIGURE 3. FACS analysis of cell surface Gal␣1-3Gal (A) and Sia␣26Gal (B) sequence in resting and activated lymphocytes. Splenocytes isolated from C57BL/6 mice were cultured with (thick line) or without (thin line) activator as described in Materials and Methods and the medium was supplemented with IL-2/IL-12 for the preparation of activated T cells. After 72 h in culture, resting or activated splenocytes were harvested and CD4, CD8 T cells, and B cells were purified as described in Materials and Methods. Purified lymphocyte cell populations were evaluated for expression of the terminal Gal␣1-3Gal and Sia␣2-6Gal sequences by FACS analysis using GS-I-B 4 and SNA lectins, respectively, as described in Materials and Methods.

2436

GLYCOSYLATION CHANGES IN ACTIVATED LYMPHOCYTES noted by Kaufmann et al. (41) to be induced rapidly following activation of T cells and diminishing within 24 h. Glycan transferase changes relevant to N-linked glycans

FIGURE 4. Unsupervised hierarchical clustering analysis of glycosyltransferases expression in fresh and activated lymphocytes. The dendrogram has been constructed using centered correlation and average linkage. The three biological replicates are shown for each sample, fresh (F) and differently activated (aIgM ⫽ anti-IgM; 2 ⫽ IL-2; 4 ⫽ IL-4; 12 ⫽ IL-12) as explained in Materials and Methods.

forms the O-linked glycan sequence NeuAc(Gc)␣2-3Gal␤1-3GalNAc and regulates the expression of PNA receptors in developing thymocytes (1, 2) and in resting and activated peripheral CD8 T cells (9) and CD4 T cells (10). Although there is only a decrease of 1.3- to 1.5-fold in the signal between fresh and activated T cells (and B cells), it is statistically significant, and appears to be sufficient to cause hyposialylation of O-glycans resulting in the PNAhigh phenotype resulting from the increased expression of the Gal␤1-3GalNAc ligand recognized by PNA (9, 10). The increase in the other enzyme, ST6GalNAc IV transferase, was previously

Of the results summarized in Table II, 13 genes relevant to the synthesis of N-linked glycans exhibited significant changes in gene expression. Seven of these are involved in the synthesis of elements of N-linked glycan structure common to all cells because they either 1) participate in the synthesis of the high mannose lipid-linked intermediate (mannosyltransferases), 2) are subunits of oligosaccharyltransferase that transfers the glycan to asparagine (DAD1, ribophorin I and II), or 3) form the ubiquitous Gal␤1– 4GlcNAc sequence that extends the branches of most complex type N-linked glycans (b4GalT1). Consistent with the constitutive expression of N-linked glycans in all cells, these genes are expressed in all resting and activated cell populations. The six genes involved in the synthesis and transfer of the lipid-linked intermediate in general showed increased expression in activated T cells, with 25 of 42 comparisons showing significant 1.5- to 2.9-fold increases in signal, consistent with the increased need for N-linked glycans in proliferating cells. The remaining six genes are involved in the synthesis of terminal sequences in N-linked (and O-linked) glycans. In contrast to the genes involved in the synthesis of the core N-glycan sequences, these genes were differentially regulated, showing both positive and negative changes in expression (Table II and Fig. 5). Of these, the ␤-galactoside ␣2-6 sialyltransferase (ST6Gal I) and ␤-galactoside ␣1-3 galactosyltransferase (␣1-3GalT) are responsible for the synthesis of the terminal sequences NeuGc␣2-6Gal␤1-4GlcNAc (42) and Gal␣1-3Gal␤1-4GlcNAc (43), respectively, that account for the major changes in terminal glycosylation of N-linked

Table II. Expression fold changes in glycosyltransferase expression in resting and activated lymphocytesa CD8 Activation Condition

CD4 Activation Condition

Subcategory

Common Name

CD4 Present Calls (Fresh: Activated)

N-linked glycan core synthesis N-glycan-transferase DAD1b P:PPP N-glycan-transferase Ribophorin I P:PPP N-glycan-transferase Ribophorin II P:PPP Mannosyltransferase ALG13 P:PPP Mannosyltransferase DPM1 P:PPP Mannosyltransferase DPM2 P:PPP Galactosyltransferase b4GalT1 P:PPP Terminal Glycosyltransferases -N- and O-linked glycans Galactosyltransferase ␣1,3GalT P:PPP Sialyltransferase ST6Gal I-Long t P:PPP Sialyltransferase ST3Gal IV A:PPP Sialyltransferase ST3Gal VI P:AAA Sialyltransferase ST8Sia IV P:PPP Sulfotransferase GlcNAc6ST-1 A:PPP Terminal glycosyltransferases - O-linked glycans Sialyltransferase ST3Gal I P:PPP Sialyltransferase ST6GalNAc IV P:PPP

IL-2

IL-2IL-12

IL-2IL-4

Fold change (Active-Fresh)

CD8 Present Calls (Fresh: Activated)

IL-2

IL-2IL-12

IL-2IL-4

Fold change (Active-Fresh)

B Cell B Cell Present Cells Fresh: Anti-IgM Fold Change Activated

GenBank Number

1.612 1.533 1.579 1.391 1.359 1.549 1.659 1.578 1.803 1.572 1.350 1.890 2.663 2.407 2.894 2.191 2.126 2.231 1.001 ⫺1.019 ⫺1.122

P:PPP P:PPP P:PPP P:PPP P:PPP P:PPP P:PPP

1.057 ⫺1.078 1.073 1.370 1.469 1.395 1.400 1.279 1.294 1.547 1.533 2.027 2.056 1.878 1.763 1.851 1.963 2.089 1.344 ⴚ1.458 ⴚ1.399

P:P P:P P:P P:P P:P P:P P:P

1.083 ⫺1.115 1.025 1.356 1.052 1.334 1.686

U83628 BC016080 NM_019642 AA215144 AB004789 NM_010073 J03880

1.920 2.067 2.085 ⴚ3.061 ⴚ3.622 ⴚ3.820 1.468 1.656 1.742 ⴚ1.549 ⴚ1.593 ⴚ1.789 ⴚ4.597 ⴚ3.685 ⴚ4.902 1.544 2.075 1.687

P:PPP P:AAA A:PPP P:AAA P:PPA A:APA

2.079 2.063 1.859 ⴚ5.939 ⴚ5.689 ⴚ5.742 1.688 1.432 1.594 ⴚ3.067 ⴚ2.884 ⴚ3.251 ⴚ6.684 ⴚ5.615 ⴚ7.057 1.499 1.742 1.460

P:P P:P A:A P:P P:P A:A

ⴚ2.765 1.293 ⫺1.027 ⫺2.564 ⫺3.135 1.042

AF297615 BB768706 BC011121 NM_018784 X86000 AB011451

ⴚ1.338 ⴚ1.298 ⴚ1.336 1.594 1.765 1.857

P:PPP P:PPP

ⴚ1.605 ⫺1.381 ⫺1.585 1.370 1.739 1.612

P:P P:P

⫺1.486 1.268

X73523 Y15779

a Mixed splenocytes pooled from 10 –30 mice were activated using either anti-CD3 (for T cells) or anti-IgM (for B cells) in the presence of cytokines (IL-2, IL-2/IL-12, or IL-2/IL-4) as described in Materials and Methods. Following purification of the desired cell type, RNA was purified and gene expression was analyzed on a single GLYCOv1 microarray. Each experiment was done in triplicate, and the data for all three experiments were analyzed together to assess statistically significant changes in gene expression. Genes were scored as being present (detected) or absent (undetected) using the Affymetrix MAS 5.0 algorithm, and are either listed in the table as present (P) or absent (A) if they received that score in at least two of the three experiments. These are summarized in the present call column for fresh cells followed by the corresponding call for each of the related activation conditions (e.g. P:AAA indicates the gene was present in fresh cells and absent in each of the three activation conditions). The expression values (levels) were calculated using the Robust Multi-array Averaging (RMA) algorithm generated by the software package RMA express, which computes a log-2 expression value for each gene (Materials and Methods). Using the RMA value calculated for fresh cells as a reference, the change in RMA value was determined for each activation condition, and is expressed as a “fold change‘, with positive values representing an increase, and negative values representing a decrease. Values for “absent” calls are in italics and values for “present” are in normal font. Values in bold indicate statistically significant differences from the values in the corresponding fresh cells. A complete list of results for all 122 glycosyltransferase and sulfotransferase genes is provided in supplementary material (table 1S). b Defender against cell death protein 1.


FIGURE 5. Changes in the expression of glycosyltransferases that form terminal sequences in N-linked glycans following activation of lymphocytes. Shown are results for genes of terminal glycosyltransferase acting on N-linked (or N- and O-linked) glycans that exhibited at least a 2-fold change in expression levels in fresh and activated CD8 T cells with IL-2/ IL-12. Each enzyme is identified by its common name and the symbol structure of the product formed as terminal sequences found on N- and O-linked glycans, with the sugar transferred by the enzyme identified by an asterisk (ⴱ). Each enzyme exhibits a unique pattern of expression relative to the others with respect to positive or negative regulation upon activation, and differential expression in T and B cells. Comparisons with other enzymes and activation conditions are summarized in Table II.

glycans observed following activation of CD8 and CD4 T cells. The 5- to 6-fold decrease in ST6Gal I, is consistent with the loss of the NeuGc␣2-6Gal sequence observed as the major structure in fresh T cells. The decrease in ST6Gal I expression was also observed by quantitative RT-PCR, which showed a 6- to 10-fold reduction (data not shown). Conversely, there was a 2-fold increase in the ␣1-3GalT, consistent with the formation of the Gal␣1-3Gal terminal sequence observed as the predominant structure in activated cells. In preliminary experiments conducted with a spotted cDNA microarray (44), changes in the expression of ST6Gal I were evident within 24 h and increased at 48 and 72 h, while the increase in ␣1-3GalT was evident by 48 h (data not shown). As diagrammed in Fig. 6, these two enzymes compete for a common substrate, Gal␤1-4GlcNAc, on growing N-linked glycan chains. Thus, the effects of the decrease in expression of ST6Gal I and increase in expression of ␣1-3GalT are amplified through their competition in the biosynthetic pathway. Conversely, in B cells, the ST6Gal I gene showed slightly increased expression (2), and the ␣1-3GalT gene showed a 3-fold

FIGURE 6. ST6Gal I and ␣1-3 GalT compete for a common substrate in terminal glycosylation of N-linked glycans. The ␤-galactoside ␣2-6 sialyltransferase (ST6Gal I) and ␤-galactoside ␣1-3 galactosyltransferase (␣1-3GalT) use the same acceptor substrate sequence on growing N-linked glycan chains, resulting in the formation of a terminal Sia␣2-6Gal␤1-4GlcNAc and Gal␣13Gal␤1-4GlcNAc sequences, respectively. The two enzymes effectively compete for the same substrate because neither can use the product of the other as a substrate. Changing the relative amounts of these two enzymes should, in principle, result in a corresponding change in the terminal sequences they produce on complex type N-glycans.

2437 decrease in RMA signal, the opposite from T cells. These results are consistent with the observed retention of N-linked glycans with the terminal NeuGc␣2-6Gal sequence in both resting and activated B cells (Fig. 2). The changes in expression of the other four genes do not appear relevant to the major changes seen in the N-glycan MALDI-TOF MS profiles documented in Fig. 2. The ST8Sia IV enzyme exhibits a dramatic decrease following activation of all three lymphocyte types. ST8Sia IV is a polysialyltransferase that transfers one or more sialic acid residues in the [NeuAc(Gc)␣2-8]nNeuAc(Gc)␣23Gal sequence on N-linked glycans of a limited number of glycoproteins including neural cell adhesion molecule (45). To date, such sialylated structures have not been reported on lymphocytes, and while they may be present in small amounts, they do not comprise an observable component of the N-glycans analyzed in this report. Two enzymes that synthesize the sequence NeuAc(Gc)␣23Gal␤1-4GlcNAc on N-linked and O-linked glycans, ST3Gal IV and ST3Gal VI (46 – 48), were differentially expressed in T cells. ST3Gal IV went from absent to present, and ST3Gal VI went from present to absent (Table II). The increase in expression of ST3Gal IV has been previously reported in activated CD4 cells following 6 –10 days of activation (11) and is believed to play a critical role in the formation of the sialyl-Lewis X linkage on O-linked glycans that serve as ligands for selectins (11, 49). However, the dramatic reduction in sialylated N-glycans in activated CD4 and CD8 T cells (Fig. 2) indicates that ST3Gal IV is not a major contributor to terminal glycosylation of N-glycans. Although a decrease in the expression of the ST3Gal VI enzyme is consistent with loss of sialylated glycans (Fig. 2), it does not account for the net loss in 6-substituted galactose and increase in 3-substituted galactose. Finally, the GlcNAc6ST-1 is a sulfotransferase that forms the Gal␤14(6S)GlcNAc sequence. Although sulfated structures are not captured in the MALDI-TOF profiling protocols used for analysis of N-glycans in this report and could have been missed, the product of this enzyme has been shown to be expressed primarily on high endothelial venules of lymph nodes and not on lymphocytes (50, 51)

Discussion Comparison of the N-glycan structures following activation of T and B lymphocytes has revealed a heretofore unrecognized change in terminal glycosylation of N-linked glycans of activated murine T lymphocytes involving the loss of charged sialylated glycans terminated with the NeuGc␣2-6Gal sequence, and an increase in uncharged glycans terminated with the Gal␣1-3Gal sequence. This

2438 change corresponds to changes in expression of the two glycosyltransferases responsible for their synthesis, a decreased expression of the sialyltransferase ST6Gal I, and increased expression of the galactosyltransferase ␣1-3GalT, respectively. In contrast to the change observed in T cells, B cells maintain their sialylated Nlinked glycans following activation, consistent with increased expression of ST6Gal I and decreased expression of ␣1-3GalT. Reports from other laboratories corroborate aspects of these findings for regulation of the ST6Gal I gene in activated lymphocytes in vivo. In particular, using an in vivo transgenic lymphocytic choriomeningitis virus model for Ag activation of CD8 cells, Kaech et al. (26) found ST6Gal I to be one of the genes that was down-regulated in CD8 effector cells 8 days after transfection. Moreover, effector cells exhibited reduced binding of the SNA that recognizes the Sia␣2-6Gal sequence (Ref. 52, and L. Baum, T. Onami, and R. Ahmed, unpublished observations). This study recapitulates in vivo the results obtained with CD8 cells in this report. Although only modest reduction of SNA binding was observed comparing native and activated CD4 cells in this study, this may be due to the fact that the residual sialylated glycans at the end of 72 h are sufficient to support significant lectin binding to other glycan classes (e.g., glycolipids). In murine B cells, increased expression of the ST6Gal I gene has been observed, mediated by a B cell-specific promoter (53). Although peak expression occurs 10 days after activation, significant increases in expression were observed within 72 h as observed in this report. (Probe sets for one of two alternatively spliced forms of ST6Gal I are shown in Table II. The probe set corresponding to the “long form” is derived from the 3⬘ end of a 4.3-kb mRNA, while the probe set for the “short form” is at the 3⬘ end of a ⬃2-kb mRNA resulting from an alternative polyA addition site 2 kb from the 3⬘ end of the 4.3-kb transcript. Although 4.3-kb message is the predominant mRNA for this gene in most human tissues (48), significant up-regulation of the “short form” was seen in B cells (see supplementary material)). The loss of the NeuGc␣2-6Gal sequence has functional implications relevant to the interaction of T cells and B cells with glycan-binding proteins. The B cell membrane marker CD22 is wellknown as a regulator of BCR signaling, and is a member of the Siglec family (Siglec-2) with an extracellular N-terminal Ig domain that recognizes the NeuGc␣2-6Gal sequence as a preferred ligand on murine cells (54, 55). CD22 interacts with glycoprotein ligands on the same cell, in cis, and on adjacent cells, in trans. Interaction of CD22 with B cell ligands in cis has been suggested to modulate the activity of CD22 as a negative regulator of B cell signaling (23, 25, 56, 57). However, CD22 was initially described as a T cell adhesion protein and has been demonstrated to interact with trans ligands on adjacent cells (23, 58, 59). Thus, differential regulation of the NeuGc␣2-6Gal sequence may modulate CD22 function through its complex interaction with cis and trans ligands, particularly in B-T cell interactions (e.g., B cell Ag presentation to T cells). The ST6Gal I transferase expression has also been proposed to modulate binding of galectin-1 to CD45 on T cells leading to cell death (19). In this case, sialylation of CD45 glycans blocks the terminal Gal␤1– 4GlcNAc-binding sites used as a ligand by galectin-1. Thus, reduced ST6Gal I expression in activated T cells could lead to increased binding of galectin-1. In this regard, following activation of CD4 and CD8 T cells, we observed significant enhancement of the binding of Erythrina cristagalli agglutinin, which binds the Gal␤1– 4GlcNAc sequence (data not shown). Concomitant with a loss of the NeuGc␣2-6Gal sequence, Nlinked glycans of activated T cells acquire the Gal␣1-3Gal sequence, the product of the galactosyltransferase, ␣1-3GalT. In humans, this enzyme is catalytically inactive, and consequently the

GLYCOSYLATION CHANGES IN ACTIVATED LYMPHOCYTES Gal␣1-3Gal sequence is not expressed. It will be of interest to assess the glycosylation changes in human lymphocytes to see whether the same loss of sialylated glycans occurs, and if so, what if any sequence replaces the Gal␣1-3Gal sequence in murine cells. With the increasing attention of the roles of glycan-binding proteins in immune function, the paucity of information on glycan structures on leukocytes has become increasingly evident, and is a limiting factor in elucidating the biology they mediate (60 – 64). The approach used in this report has general use for detecting changes in glycosylation of closely related leukocyte cell populations (e.g., pre-/postdifferentiation or activation, immature/mature, etc.) and establishing the biosynthetic basis for those changes. With present technology, the MALDI-TOF MS and supporting MS/MS and methylation analysis experiments provide meaningful data on the most abundant glycans. However, some subsets of glycans, for example sulfated structures, would be missed using protocols described in this report. Perhaps even more important, literally hundreds of minor glycans can be detected by MS analysis, but the subsequent annotation and verification of structure is prohibitive. However, progress for developing automatic methods of annotation with sophisticated algorithms is being made (65– 67), and technology advances in sample preparation and analysis will rapidly evolve. Combining glycan structure analysis and global expression analysis using oligonucleotide microarrays may provide increasingly rich information about the regulation of glycosylation of pure cell populations responding to environmental signals such as those studied here. It is estimated that there may be a total of ⬃250 glycan transferase genes in the murine (and human) genomes. Although the microarray used for this study (GLYCOv1 chip) contained 122 unique murine glycosyltransferase genes, an updated version, GLYCOv3, contains ⬃200 murine glycan transferase genes, providing more complete coverage of the biosynthetic pathways. An inherent problem with microarray data is that some probe sets “do not work”. Two genes in particular, FucT-VII and core 2 GlcNAc transferase, known to be involved in Sialyl-Lewis X selectin ligand formation on O-linked glycans of CD4 Th1 T cells (11–16, 68), were not detected (see supplemental data). However, our recent experience is that redesign of the probe sets can largely remedy this problem and should lead to increasingly powerful data sets. Even with a complete set of genes, changes detected in gene expression may not be reflected in major changes in glycan structure (e.g., changes in ST3Gal VI and ST8Sia IV in this report), because not all enzymes will be rate limiting, and some may be expressed at levels below the threshold needed to compete with other enzymes in the pathway. However, recent efforts to develop algorithms that take global microarray data to predict glycan structure show promise (69), and could evolve, through information gleaned from data sets of expression data from cells with known glycan profiles, to recognize significant from insignificant changes in gene expression. Current efforts to combined advances in glycan structure analysis and technologies for functional gene expression analysis are likely to converge to provide a systems biology approach to analysis of glycan structure and function that will facilitate future investigations into roles of glycan-binding proteins in immune cell function (70).

Acknowledgments We thank Sarah Lustig for technical help and Anna Tran-Crie for assistance with preparation of the manuscript.

Disclosures The authors have no financial conflict of interest.


References 1. Gillespie, W., J. C. Paulson, S. Kelm, M. Pang, and L. G. Baum. 1993. Regulation of ␣2,3-sialyltransferase expression correlates with conversion of peanut agglutinin PNA⫹ to PNA⫺ phenotype in developing thymocytes. J. Biol. Chem. 268: 3801–3804. 2. Priatel, J. J., D. Chui, N. Hiraoka, C. J. Simmons, K. B. Richardson, D. M. Page, M. Fukuda, N. M. Varki, and J. D. Marth. 2000. The ST3Gal-I sialyltransferase controls CD8⫹ T lymphocyte homeostasis by modulating O-glycan biosynthesis. Immunity 12: 273–283. 3. Reisner, Y., M. Linker-Israeli, and N. Sharon. 1976. Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin. Cell. Immunol. 25: 129 –134. 4. Wu, W., J. A. Punt, L. Granger, S. O. Sharrow, and K. P. Kearse. 1997. Developmentally regulated expression of peanut agglutinin (PNA)-specific glycans on murine thymocytes. Glycobiology 7: 349 –356. 5. Moody, A. M., S. J. North, B. Reinhold, S. J. Van Dyken, M. E. Rogers, M. Panico, A. Dell, H. R. Morris, J. D. Marth, and E. L. Reinherz. 2003. Sialic acid capping of CD8␤ core 1-O-glycans controls thymocyte-major histocompatibility complex class I interaction. J. Biol. Chem. 278: 7240 –7246. 6. Pappu, B. P., and P. A. Shrikant. 2004. Alteration of cell surface sialylation regulates antigen-induced naive CD8⫹ T cell responses. J. Immunol. 173: 275–284. 7. Starr, T. K., M. A. Daniels, M. M. Lucido, S. C. Jameson, and K. A. Hogquist. 2003. Thymocyte sensitivity and supramolecular activation cluster formation are developmentally regulated: a partial role for sialylation. J. Immunol. 171: 4512– 4520. 8. Galvan, M., K. Murali-Krishna, L. L. Ming, L. Baum, and R. Ahmed. 1998. Alterations in cell surface carbohydrates on T cells from virally infected mice can distinguish effector/memory CD8⫹ T cells from naive cells. J. Immunol. 161: 641– 648. 9. Amado, M., Q. Yan, E. M. Comelli, B. E. Collins, and J. C. Paulson. 2004. Peanut agglutinin high phenotype of activated CD8⫹ T cells results from de novo synthesis of CD45 glycans. J. Biol. Chem. 279: 36689 –36697. 10. Grabie, N., M. W. Delfs, Y. C. Lim, J. R. Westrich, F. W. Luscinskas, and A. H. Lichtman. 2002. ␤-Galactoside ␣2,3-sialyltransferase-I gene expression during Th2 but not Th1 differentiation: implications for core 2-glycan formation on cell surface proteins. Eur. J. Immunol. 32: 2766 –2772. 11. Blander, J. M., I. Visintin, C. A. Janeway, Jr., and R. Medzhitov. 1999. ␣(1,3)fucosyltransferase VII and ␣(2,3)-sialyltransferase IV are up-regulated in activated CD4 T cells and maintained after their differentiation into Th1 and migration into inflammatory sites. J. Immunol. 163: 3746 –3752. 12. Wagers, A. J., and G. S. Kansas. 2000. Potent induction of ␣(1,3)-fucosyltransferase VII in activated CD4⫹ T cells by TGF-␤1 through a p38 mitogen-activated protein kinase-dependent pathway. J. Immunol. 165: 5011–5016. 13. Nakayama, F., Y. Teraki, T. Kudo, A. Togayachi, H. Iwasaki, T. Tamatani, S. Nishihara, Y. Mizukawa, T. Shiohara, and H. Narimatsu. 2000. Expression of cutaneous lymphocyte-associated antigen regulated by a set of glycosyltransferases in human T cells: involvement of ␣1,3-fucosyltransferase VII and ␤1,4galactosyltransferase I. J. Invest. Dermatol. 115: 299 –306. 14. Snapp, K. R., C. E. Heitzig, L. G. Ellies, J. D. Marth, and G. S. Kansas. 2001. Differential requirements for the O-linked branching enzyme core 2 ␤1-6-N-glucosaminyltransferase in biosynthesis of ligands for E-selectin and P-selectin. Blood 97: 3806 –3811. 15. Knibbs, R. N., R. A. Craig, S. Natsuka, A. Chang, M. Cameron, J. B. Lowe, and L. M. Stoolman. 1996. The fucosyltransferase FucT-VII regulates E-selectin ligand synthesis in human T cells. J. Cell Biol. 133: 911–920. 16. Borges, E., G. Pendl, R. Eytner, M. Steegmaier, O. Zollner, and D. Vestweber. 1997. The binding of T cell-expressed P-selectin glycoprotein ligand-1 to E- and P-selectin is differentially regulated. J. Biol. Chem. 272: 28786 –28792. 17. Underhill, G. H., D. G. Zisoulis, K. P. Kolli, L. G. Ellies, J. D. Marth, and G. S. Kansas. 2005. A crucial role for T-bet in selectin ligand expression in T helper 1 (Th1) cells. Blood 106: 3867–3873. 18. Demetriou, M., M. Granovsky, S. Quaggin, and J. W. Dennis. 2001. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409: 733–739. 19. Amano, M., M. Galvan, J. He, and L. G. Baum. 2003. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin1-induced CD45 clustering, phosphatase modulation, and T cell death. J. Biol. Chem. 278: 7469 –7475. 20. Powell, L. D., D. Sgroi, E. R. Sjoberg, I. Stamenkovic, and A. Varki. 1993. Natural ligands of the B cell adhesion molecule CD22 ␤ carry N-linked oligosaccharides with ␣-2,6-linked sialic acids that are required for recognition. J. Biol. Chem. 268: 7019 –7027. 21. Braesch-Andersen, S., and I. Stamenkovic. 1994. Sialylation of the B lymphocyte molecule CD22 by ␣2,6-sialyltransferase is implicated in the regulation of CD22mediated adhesion. J. Biol. Chem. 269: 11783–11786. 22. Sgroi, D., G. A. Koretzky, and I. Stamenkovic. 1995. Regulation of CD45 engagement by the B-cell receptor CD22. Proc. Natl. Acad. Sci. USA 92: 4026 – 4030. 23. Collins, B. E., O. Blixt, A. R. DeSieno, N. Bovin, J. D. Marth, and J. C. Paulson. 2004. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl. Acad. Sci. USA 101: 6104 – 6109. 24. Tedder, T. F., J. Tuscano, S. Sato, and J. H. Kehrl. 1997. CD22, a B lymphocytespecific adhesion molecule that regulates antigen receptor signaling. Annu. Rev. Immunol. 15: 481–504.

2439 25. Tedder, T. F., J. C. Poe, and K. M. Haas. 2005. CD22: a multifunctional receptor that regulates b lymphocyte survival and signal transduction. Adv. Immunol. 88: 1–50. 26. Kaech, S. M., S. Hemby, E. Kersh, and R. Ahmed. 2002. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 111: 837– 851. 27. Piller, F., V. Piller, R. I. Fox, and M. Fukuda. 1988. Human T-lymphocyte activation is associated with changes in O-glycan biosynthesis. J. Biol. Chem. 263: 15146 –15150. 28. Lowe, J. B. 2002. Glycosylation in the control of selectin counter-receptor structure and function. Immunol. Rev. 186: 19 –36. 29. Comelli, E. M., S. R. Head, T. Gilmartin, T. Whisenant, S. M. Haslam, S. J. North, N. K. Wong, T. Kudo, H. Narimatsu, J. D. Esko, et al. 2006. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology 16: 117–131. 30. Irizarry, R. A., B. M. Bolstad, F. Collin, L. M. Cope, B. Hobbs, and T. P. Speed. 2003. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31: e15. 31. Zar, J. H. 1999. Biostatistical Analysis, 4th Ed. Prentice Hall, Upper Saddle River. 32. Dunnett, C. W. 1955. A multiple comparisons procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50: 1096 –1121. 33. Sutton-Smith, M., H. R. Morris, and A. Dell. 2000. Tetrahedron. Asymmetry 11: 363–364. 34. Sutton-Smith, M., and A. Dell. 2006. Analysis of carbohydrates/glycoproteins by mass spectroscopy. In Cell Biology: A Laboratory Handbook, 3rd Ed. J. Celis, ed. Academic Press, San Diego, pp. 415– 425. 35. Goldberg, D., M. Sutton-Smith, J. Paulson, and A. Dell. 2005. Automatic annotation of matrix-assisted laser desorption/ionization N-glycan spectra. Proteomics 5: 865– 875. 36. Anderson, D. R., P. H. Atkinson, and W. J. Grimes. 1985. Major carbohydrate structures at five glycosylation sites on murine IgM determined by high resolution 1 H-NMR spectroscopy. Arch. Biochem. Biophys. 243: 605– 618. 37. Bergwerff, A. A., C. J. Stroop, B. Murray, A. P. Holtorf, G. Pluschke, J. Van Oostrum, J. P. Kamerling, and J. F. Vliegenthart. 1995. Variation in N-linked carbohydrate chains in different batches of two chimeric monoclonal IgG1 antibodies produced by different murine SP2/0 transfectoma cell subclones. Glycoconj. J. 12: 318 –330. 38. Yoshida, T., N. Takahashi, and I. Nakashima. 1991. Cell type and maturation stage-dependent polymorphism of N-linked oligosaccharides on murine lymphocytes and lymphoma cells. Mol. Immunol. 28: 1121–1130. 39. Lederer, J. A., V. L. Perez, L. DesRoches, S. M. Kim, A. K. Abbas, and A. H. Lichtman. 1996. Cytokine transcriptional events during helper T cell subset differentiation. J. Exp. Med. 184: 397– 406. 40. Szabo, S. J., B. M. Sullivan, S. L. Peng, and L. H. Glimcher. 2003. Molecular mechanisms regulating Th1 immune responses. Annu. Rev. Immunol. 21: 713–758. 41. Kaufmann, M., C. Blaser, S. Takashima, R. Schwartz-Albiez, S. Tsuji, and H. Pircher. 1999. Identification of an ␣2,6-sialyltransferase induced early after lymphocyte activation. Int. Immunol. 11: 731–738. 42. Hennet, T., D. Chui, J. C. Paulson, and J. D. Marth. 1998. Immune regulation by the ST6Gal sialyltransferase. Proc. Natl. Acad. Sci. USA 95: 4504 – 4509. 43. Thall, A. D., H. S. Murphy, and J. B. Lowe. 1996. ␣1,3-Galactosyltransferasedeficient mice produce naturally occurring cytotoxic anti-Gal antibodies. Transplant. Proc. 28: 556 –557. 44. Comelli, E. M., M. Amado, S. R. Head, and J. C. Paulson. 2002. Custom microarray for glycobiologists: considerations for glycosyltransferase gene expression profiling. Biochem. Soc. Symp. 69: 135–142. 45. Angata, K., M. Suzuki, and M. Fukuda. 2002. ST8Sia II and ST8Sia IV polysialyltransferases exhibit marked differences in utilizing various acceptors containing oligosialic acid and short polysialic acid: the basis for cooperative polysialylation by two enzymes. J. Biol. Chem. 277: 36808 –36817. 46. Okajima, T., S. Fukumoto, H. Miyazaki, H. Ishida, M. Kiso, K. Furukawa, and T. Urano. 1999. Molecular cloning of a novel ␣2,3-sialyltransferase (ST3Gal VI) that sialylates type II lactosamine structures on glycoproteins and glycolipids. J. Biol. Chem. 274: 11479 –11486. 47. Sasaki, K., E. Watanabe, K. Kawashima, S. Sekine, T. Dohi, M. Oshima, N. Hanai, T. Nishi, and M. Hasegawa. 1993. Expression cloning of a novel Gal ␤(1-3/1-4) GlcNAc ␣2,3-sialyltransferase using lectin resistance selection. J. Biol. Chem. 268: 22782–22787. 48. Kitagawa, H., and J. C. Paulson. 1994. Differential expression of five sialyltransferase genes in human tissues. J. Biol. Chem. 269: 17872–17878. 49. Ellies, L. G., M. Sperandio, G. H. Underhill, J. Yousif, M. Smith, J. J. Priatel, G. S. Kansas, K. Ley, and J. D. Marth. 2002. Sialyltransferase specificity in selectin ligand formation. Blood 100: 3618 –364. 50. Kawashima, H., B. Petryniak, N. Hiraoka, J. Mitoma, V. Huckaby, J. Nakayama, K. Uchimura, K. Kadomatsu, T. Muramatsu, J. B. Lowe, and M. Fukuda. 2005. N-acetylglucosamine-6-O-sulfotransferases 1 and 2 cooperatively control lymphocyte homing through L-selectin ligand biosynthesis in high endothelial venules. Nat. Immunol. 6: 1096 –1104. 51. Uchimura, K., J. M. Gauguet, M. S. Singer, D. Tsay, R. Kannagi, T. Muramatsu, U. H. von Andrian, and S. D. Rosen. 2005. A major class of L-selectin ligands is eliminated in mice deficient in two sulfotransferases expressed in high endothelial venules. Nat. Immunol. 6: 1105–1113. 52. Onami, T. M., J. D. Hernandez, S. M. Kaech, L. G. Baum, and R. Ahmed. 2003. Glycobiology and immunity. Glycobiology 13: 882. 53. Wuensch, S. A., R. Y. Huang, J. Ewing, X. Liang, and J. T. Lau. 2000. Murine B cell differentiation is accompanied by programmed expression of multiple

2440

54.

55. 56.

57.

58.

59.

60. 61.

novel ␤-galactoside ␣2,6-sialyltransferase mRNA forms. Glycobiology 10: 67–75. Blixt, O., B. E. Collins, I. M. van den Nieuwenhof, P. R. Crocker, and J. C. Paulson. 2003. Sialoside specificity of the siglec family assessed using novel multivalent probes: identification of potent inhibitors of myelin-associated glycoprotein. J. Biol. Chem. 278: 31007–31019. Crocker, P. R. 2002. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling. Curr. Opin. Struct. Biol. 12: 609 – 615. Collins, B. E., B. A. Smith, P. Bengtson, and J. C. Paulson. 2006. Ablation of CD22 in ligand-deficient mice restores B cell receptor signaling. Nat. Immunol. 7: 199 –206. Poe, J. C., Y. Fujimoto, M. Hasegawa, K. M. Haas, A. S. Miller, I. G. Sanford, C. B. Bock, M. Fujimoto, and T. F. Tedder. 2004. CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms. Nat. Immunol. 5: 1078 –1087. Lanoue, A., F. D. Batista, M. Stewart, and M. S. Neuberger. 2002. Interaction of CD22 with ␣2,6-linked sialoglycoconjugates: innate recognition of self to dampen B cell autoreactivity? Eur. J. Immunol. 32: 348 –355. Stamenkovic, I., D. Sgroi, A. Aruffo, M. S. Sy, and T. Anderson. 1991. The B lymphocyte adhesion molecule CD22 interacts with leukocyte common antigen CD45RO on T cells and ␣2-6 sialyltransferase: CD75, on B cells. Cell 66: 1133–1144. Crocker, P. R. 2005. Siglecs in innate immunity. Curr. Opin. Pharmacol. 5: 431– 434. Geijtenbeek, T. B., S. J. van Vliet, A. Engering, B. A. ’t Hart, and Y. van Kooyk. 2004. Self- and nonself-recognition by C-type lectins on dendritic cells. Annu. Rev. Immunol. 22: 33–54.

GLYCOSYLATION CHANGES IN ACTIVATED LYMPHOCYTES 62. Rabinovich, G. A., and A. Gruppi. 2005. Galectins as immunoregulators during infectious processes: from microbial invasion to the resolution of the disease. Parasite Immunol. 27: 103–114. 63. van Die, I., and R. D. Cummings. 2006. Glycans modulate immune responses in helminth infections and allergy. Chem. Immunol. Allergy 90: 91–112. 64. Moody, D. B., D. M. Zajonc, and I. A. Wilson. 2005. Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5: 387–384. 65. Joshi, H. J., M. J. Harrison, B. L. Schulz, C. A. Cooper, N. H. Packer, and N. G. Karlsson. 2004. Development of a mass fingerprinting tool for automated interpretation of oligosaccharide fragmentation data. Proteomics 4: 1650 –1664. 66. von der Lieth, C. W., A. Bohne-Lang, K. K. Lohmann, and M. Frank. 2004. Bioinformatics for glycomics: status, methods, requirements and perspectives. Brief Bioinform. 5: 164 –178. 67. Lohmann, K. K., and C. W. von der Lieth. 2004. GlycoFragment and GlycoSearchMS: web tools to support the interpretation of mass spectra of complex carbohydrates. Nucleic Acids Res. 32: W261–W266. 68. Wagers, A. J., C. M. Waters, L. M. Stoolman, and G. S. Kansas. 1998. Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on ␣1,3-fucosyltransferase VII gene expression. J. Exp. Med. 188: 2225–2231. 69. Kawano, S., K. Hashimoto, T. Miyama, S. Goto, and M. Kanehisa. 2005. Prediction of glycan structures from gene expression data based on glycosyltransferase reactions. Bioinformatics 21: 3976 –3982. 70. Raman, R., S. Raguram, G. Venkataraman, J. C. Paulson, and R. Sasisekharan. 2005. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nat. Methods 2: 817– 824.